Sugi Predict

Sugi Predict / Compounds / SCHEMBL1847432

SCHEMBL1847432

SCHEMBL1847432

CC(=O)O[C@@H]1[C@H]([C@H]2COC(C)(C)O2)O[C@@H]2OC(C)(C)O[C@@H]21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 11/20 0.64
▸ CA1 P00915 7/20 0.64
▸ CA9 Q16790 4/20 0.64
▸ MMP1 P03956 1/20 0.34
▸ MMP3 P08254 1/20 0.34
▸ MMP9 P14780 1/20 0.34
▸ ADAM17 P78536 1/20 0.34
▸ CA12 O43570 2/20 0.33
▸ CA4 P22748 2/20 0.33
▸ CA5A P35218 2/20 0.33
▸ CA7 P43166 2/20 0.33
▸ CA14 Q9ULX7 2/20 0.33
▸ CA5B Q9Y2D0 2/20 0.33
▸ CA6 P23280 1/20 0.33
▸ CA13 Q8N1Q1 1/20 0.33
▸ ABCB1 P08183 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ LMNA P02545 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ THPO P40225 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26457815 1.00 CA2 (0.64) CA2CA1CA9MMP1MMP3
SCHEMBL14441192 1.00 CA2 (0.64) CA2CA1CA9MMP1MMP3
SCHEMBL27174720 1.00 CA2 (0.64) CA2CA1CA9MMP1MMP3
SCHEMBL16307847 1.00 CA2 (0.64) CA2CA1CA9MMP1MMP3
SCHEMBL10883648 1.00 CA2 (0.64) CA2CA1CA9MMP1MMP3
SCHEMBL15254185 0.92 CA2 (0.64) CA2CA1CA9MMP1MMP3
SCHEMBL15254186 0.90 CA2 (0.63) CA2CA1CA9CA12CA4
SCHEMBL15254188 0.90 CA2 (0.63) CA2CA1CA9CA12CA4
SCHEMBL14839125 0.89 CA2 (0.50) CA2CA1CA9MMP1MMP3
SCHEMBL2672023 0.88 CA2 (0.60) CA2CA1CA9CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110869378-B Compounds for preventing and treating diseases and uses thereof 卡莱克汀科学有限责任公司 2023-10-13 — — CN disclosed
US-20230137160-A1 LARGE SCALE PROCESS FOR PREPARING 1,2,4, 6-TETRA-O-ACETYL-3-AZIDO-3-DEOXY-D-GALACTOPYRANOSIDE GALECTO BIOTECH AB (DK) 2023-05-04 — — US disclosed
US-20230137160-A1 LARGE SCALE PROCESS FOR PREPARING 1,2,4, 6-TETRA-O-ACETYL-3-AZIDO-3-DEOXY-D-GALACTOPYRANOSIDE GALECTO BIOTECH AB (DK) 2023-05-04 — — US disclosed
EP-4126893-A1 LARGE SCALE PROCESS FOR PREPARING 1,2,4, 6-TETRA-0-ACETYL-3-AZID0-3-DE0XY-D-GALACT0PYRAN0SIDE Galecto Biotech AB (DK) 2023-02-08 — — EP disclosed
WO-2021198160-A1 LARGE SCALE PROCESS FOR PREPARING 1,2,4, 6-TETRA-0-ACETYL-3-AZID0-3-DE0XY-D-GALACT0PYRAN0SIDE GALECTO BIOTECH AB (DK) 2021-10-07 — — WO disclosed
US-20200061095-A1 Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof GALECTIN SCIENCES, LLC 2020-02-27 — — US disclosed
US-8846910-B2 Matrix metalloproteinase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2014-09-30 — — US disclosed
US-8816073-B2 Matrix metalloproteinase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2014-08-26 — — US disclosed
US-20130302378-A1 MATRIX METALLOPROTEINASE INHIBITORS SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2013-11-14 — — US disclosed
US-20130295141-A1 MATRIX METALLOPROTEINASE INHIBITORS SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2013-11-07 — — US disclosed
US-8507670-B2 Matrix metalloproteinase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-08-13 — — US disclosed
EP-2074093-B1 PROCESS FOR PREPARING MATRIX METALLOPROTEINASE INHIBITORS AND CHIRAL AUXILIARY THEREFOR RANBAXY LAB LTD (IN) 2012-10-10 — — EP disclosed
EP-2474531-A2 Matrix metalloproteinase inhibitors Ranbaxy Laboratories Limited (IN) 2012-07-11 — — EP disclosed
EP-2322507-A1 Matrix metalloproteinase inhibitors Ranbaxy Laboratories Limited (IN) 2011-05-18 — — EP disclosed
US-20100081610-A1 MATRIX METALLOPROTEINASE INHIBITORS SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2010-04-01 — — US disclosed
EP-2074093-A2 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2009-07-01 — — EP disclosed
WO-2008023336-A2 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130302378-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP8, MMP25 CA2 746/4885CA1 694/4885CA9 635/4885
US-20230137160-A1 LARGE SCALE PROCESS FOR PREPARING 1,2,4, 6-TETRA-O-ACETYL-3-AZIDO-3-DEOXY-D-GALACTOPYRANOSIDE FUT6, FUT5, ST6GAL1 CA2 1562/4885CA1 286/4885CA9 141/4885
US-20200061095-A1 Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof LGALS1, LGALS2, LGALS4 CA2 2953/4885CA1 4150/4885CA9 2527/4885
US-20130295141-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP8, MMP25 CA2 746/4885CA1 694/4885CA9 635/4885
US-20100081610-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP8, MMP12 CA2 841/4885CA1 632/4885CA9 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.